Detrimental effects of verapamil in patients with primary pulmonary hypertension

M. Packer, N. Medina, M. Yushak, I. Wiener

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapamil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20% decline in pulmonary vascular resistance and a 27% decrease in mean pulmonary atrial pressure without significant changes in systemic vascular resistance. One patient who received verapamil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42%) and increase in right ventricular filling pressure (50%), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest. In conclusion, although verapamil appears to exert preferential vasodilator effects on the pulmonary circulation, its negative inotropic effects may be particularly detrimental to patients with primary pulmonary hypertension who have pre-existing right ventricular dysfunction; hence, treatment with verapamil is not recommended in such cases.

Original languageEnglish (US)
Pages (from-to)106-111
Number of pages6
JournalBritish Heart Journal
Volume52
Issue number1
StatePublished - 1984

Fingerprint

Verapamil
Pulmonary Circulation
Vasodilator Agents
Vascular Resistance
Hemodynamics
Pharmaceutical Preparations
Right Ventricular Dysfunction
Right Ventricular Function
Atrial Pressure
Ventricular Pressure
Calcium Channels
Heart Arrest
Pulmonary Hypertension
Hypotension
Familial Primary Pulmonary Hypertension
Therapeutics
Stroke
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Packer, M., Medina, N., Yushak, M., & Wiener, I. (1984). Detrimental effects of verapamil in patients with primary pulmonary hypertension. British Heart Journal, 52(1), 106-111.

Detrimental effects of verapamil in patients with primary pulmonary hypertension. / Packer, M.; Medina, N.; Yushak, M.; Wiener, I.

In: British Heart Journal, Vol. 52, No. 1, 1984, p. 106-111.

Research output: Contribution to journalArticle

Packer, M, Medina, N, Yushak, M & Wiener, I 1984, 'Detrimental effects of verapamil in patients with primary pulmonary hypertension', British Heart Journal, vol. 52, no. 1, pp. 106-111.
Packer, M. ; Medina, N. ; Yushak, M. ; Wiener, I. / Detrimental effects of verapamil in patients with primary pulmonary hypertension. In: British Heart Journal. 1984 ; Vol. 52, No. 1. pp. 106-111.
@article{289d1d3f4bbc4741a37dd45cba7a3b2d,
title = "Detrimental effects of verapamil in patients with primary pulmonary hypertension",
abstract = "Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapamil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20{\%} decline in pulmonary vascular resistance and a 27{\%} decrease in mean pulmonary atrial pressure without significant changes in systemic vascular resistance. One patient who received verapamil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42{\%}) and increase in right ventricular filling pressure (50{\%}), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest. In conclusion, although verapamil appears to exert preferential vasodilator effects on the pulmonary circulation, its negative inotropic effects may be particularly detrimental to patients with primary pulmonary hypertension who have pre-existing right ventricular dysfunction; hence, treatment with verapamil is not recommended in such cases.",
author = "M. Packer and N. Medina and M. Yushak and I. Wiener",
year = "1984",
language = "English (US)",
volume = "52",
pages = "106--111",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Detrimental effects of verapamil in patients with primary pulmonary hypertension

AU - Packer, M.

AU - Medina, N.

AU - Yushak, M.

AU - Wiener, I.

PY - 1984

Y1 - 1984

N2 - Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapamil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20% decline in pulmonary vascular resistance and a 27% decrease in mean pulmonary atrial pressure without significant changes in systemic vascular resistance. One patient who received verapamil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42%) and increase in right ventricular filling pressure (50%), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest. In conclusion, although verapamil appears to exert preferential vasodilator effects on the pulmonary circulation, its negative inotropic effects may be particularly detrimental to patients with primary pulmonary hypertension who have pre-existing right ventricular dysfunction; hence, treatment with verapamil is not recommended in such cases.

AB - Calcium channel blockade provides a logical approach to the treatment of pulmonary hypertension because these drugs exert direct vasodilator effects in the highly constricted pulmonary circulation. To determine the effectiveness of verapamil in the treatment of primary pulmonary hypertension the haemodynamic effects of the drug were evaluated in seven patients with this disorder; 10 mg was given intravenously to six patients and 120 mg orally to one patient. Verapamil produced a 20% decline in pulmonary vascular resistance and a 27% decrease in mean pulmonary atrial pressure without significant changes in systemic vascular resistance. One patient who received verapamil 480 mg orally daily for three months showed sustained haemodynamic and clinical improvement. Concomitant with its beneficial effects on the pulmonary circulation, however, verapamil produced a pronounced decrease in right ventricular stroke work index (42%) and increase in right ventricular filling pressure (50%), indicating a direct depressant effect of the drug on right ventricular function. In one patient these cardiodepressant effects were sufficiently pronounced to produce severe hypotension and cardiac arrest. In conclusion, although verapamil appears to exert preferential vasodilator effects on the pulmonary circulation, its negative inotropic effects may be particularly detrimental to patients with primary pulmonary hypertension who have pre-existing right ventricular dysfunction; hence, treatment with verapamil is not recommended in such cases.

UR - http://www.scopus.com/inward/record.url?scp=0021227273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021227273&partnerID=8YFLogxK

M3 - Article

C2 - 6743418

AN - SCOPUS:0021227273

VL - 52

SP - 106

EP - 111

JO - Heart

JF - Heart

SN - 1355-6037

IS - 1

ER -